Based on earlier findings on the role of IGF1 in low-grade ovarian carcinomas [46], as well as in in vitro studies in hepatocellular carcinoma, a phase II clinical trial is currently underway using the IGF-1R/IR dual receptor tyrosine kinase inhibitor OSI-906 (clinicaltrials.gov). The gene discussed is IGF1; the disease is ovarian carcinoma.